U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Emergency Preparedness | Drugs
  4. Coronavirus (COVID-19) | Drugs
  1. Emergency Preparedness | Drugs

Coronavirus (COVID-19) | Drugs

The Center for Drug Evaluation and Research (CDER) is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic.

COVID-19 Therapeutics

Sub-Topic Paragraphs

Overview and Coronavirus Treatment Acceleration Program

More CDER Activities

Clinical Trial Conduct

Coordinating and managing responses to stakeholder inquiries on Clinical Trial Conduct during the COVID-19 pandemic

Drug Imports

Regulatory flexibility for imports related to the COVID-19 pandemic

Drug Registration and Listing

Ensuring companies manufacturing drugs to address the COVID-19 public health emergency can quickly register and list products with FDA

Drug Shortages

Monitoring drug supply chain for impact of COVID-19 pandemic, and working with industry to prevent and alleviate shortages

Fraudulent Activity

Protecting Americans from fraudulent/unproven products for the treatment or prevention of COVID-19

Include/exclude header

Hand Sanitizers

Help meet the increased demand for hand sanitizers during the COVID-19 public health emergency

Safety Monitoring

View FAERS Public Dashboard for COVID-19 emergency use authorization (EUA) products

Additional Resources

COVID-19 Treatment Hub

Provides physicians, patients, and caregivers with information about the latest research in the fight against COVID-19

Paragraph Header

Contact Point
Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993

Toll Free
(855) 543-3784
(301) 796-3400

Hours Available

CDER Division of Drug Information

For Updates on Twitter follow

Contact Point Twitter


Your source for the latest drug information.
Know the moment it happens.

Back to Top